SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CMTR-CHEMTRAK FDA OK
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: kim p. sell who wrote (8)7/5/1996 6:28:00 AM
From: Jonathan Luu   of 1172
 
To All,
As reported in their 10-K, there are 8 to 10 million H. pylori test performed each year in the U.S. How much of that market can they realistically expect to capture? There is a H. pylori test already in the market, developed by Quidel (QDEL). Does anyone know how Chemtrak's test compares to theirs and could this have had an effect on the stock heading lower even after FDA approval of its test? Although, I assume their deal with Astra Merck should give their test a big advantage over that of QDEL's.

With additional approvals of the HIV test and Theophylline test slated for sometime this year, I see this dip in the stock after approval of their H. pylori test as a great opportunity to add on to my position in this company!!! Comments?

jonathan
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News